Fig. 6.
![Fig. 6. The influence of increased neutrophil counts during G-CSF therapy on ADCC against SK-BR–3 breast cancer cells was investigated in the presence of 0.4 μg/mL of BsAb (A77 × 520C9) directed to HER-2/neu and FcαRI. As effector cell source, 50 μL whole blood from patients before G-CSF (before), after 3 and 7 days of G-CSF (3 days and 7 days, respectively), or after G-CSF treatment (after) were compared. During G-CSF therapy, significant enhancement of BsAb-mediated ADCC was paralleled by significant increases in neutrophil numbers (P < .05, indicated by an asterisk [*]). Results from three experiments are presented as mean ± SEM of % specific lysis. (○), No antibody; (▴), (A77 × 520C9); (•), PMN count.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/90/11/10.1182_blood.v90.11.4485/3/bl_0031f6.jpeg?Expires=1724259933&Signature=SRGCk8-N95e9jVt0E2odxnFraRh~zkONigHGcSevO47GnIn56koSgrdJFAYQ7TYP5AmSYiLxUU7sSwbOaafW03WZAKtLV~btTXMg0r8bcu09pWYPX8X606x1i7bOpIaYDN~h6zYe13cBcX~xc0ht2NCI1jJeNlmImr-mr5iGadNCtlZ2dqQKoeJLPqVpbuUBC-dTAMK63SaIPQn47oefVDprkSoZ4b~06G4D5U9bKOkLSCBfRAvsUkQEA~AcDzJbfJ-OwPEjUOGiyZu-~mxMTweXHNGoIAOJVaJc~E3PJZGO-~SDVVW1MDRFyH~djC0NYhYwQhqKqv4Nk~7W-Wf68Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
The influence of increased neutrophil counts during G-CSF therapy on ADCC against SK-BR–3 breast cancer cells was investigated in the presence of 0.4 μg/mL of BsAb (A77 × 520C9) directed to HER-2/neu and FcαRI. As effector cell source, 50 μL whole blood from patients before G-CSF (before), after 3 and 7 days of G-CSF (3 days and 7 days, respectively), or after G-CSF treatment (after) were compared. During G-CSF therapy, significant enhancement of BsAb-mediated ADCC was paralleled by significant increases in neutrophil numbers (P < .05, indicated by an asterisk [*]). Results from three experiments are presented as mean ± SEM of % specific lysis. (○), No antibody; (▴), (A77 × 520C9); (•), PMN count.
